Navigation Links
Lexicon Announces Completion of Public Offering of Common Stock
Date:10/14/2009

THE WOODLANDS, Texas, Oct. 14 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of its previously-announced public offering of shares of its common stock. The offering included an aggregate of 38,333,332 shares of Lexicon's common stock after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares. Of this total, 22,878,187 shares were offered through the underwriters and 15,455,145 shares are being purchased by Invus, including 2,015,888 shares being purchased by Invus pursuant to its right to purchase additional shares. Lexicon expects to receive proceeds from Invus' exercise of its right to purchase additional shares on October 15, 2009. The net proceeds to Lexicon from the offering are approximately $55.2 million, after deducting the underwriting discount and estimated offering expenses and giving effect to the anticipated receipt of proceeds from Invus' exercise of its right to purchase additional shares.

The shares were offered pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. Morgan Stanley acted as the sole book-runner for the offering, with Thomas Weisel Partners LLC acting as co-manager.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities was made only by means of a final prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone: (866) 718-1649, or by emailing prospectus@morganstanley.com.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain the final prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.

Safe Harbor Statement

This press release contains "forward-looking" statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipated," "will," "proposed," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements. Additional risks and uncertainties relating to Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission and under the heading "Risk Factors" in the final prospectus supplement related to the public offering filed with the Securities and Exchange Commission on October 8, 2009. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Pricing of Common Stock in Public Offering
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
11. China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... CHICAGO, Ill. , Feb. 11, 2016 /PRNewswire/ ... of the AbbVie Rheumatology Scholarship, designed to provide ... rheumatologic disease as they pursue higher education goals. ... each for the 2016-2017 school year. The AbbVie ... Tracie Haas , vice president, corporate social ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus Pharmacy ... providing high-quality specialty pharmacy care for those suffering ... it has achieved full Specialty Pharmacy Accreditation from ... dedicated to promoting health care quality through accreditation, ... --> The URAC accreditation process demonstrates ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... use the action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its ... the Atlanta-area healthcare system. Details of the contract were not disclosed. , As ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... Florida ... Bay Lightning take on the St. Louis Blues at the Amalie Arena. The puck ... portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... healthcare industry, ranked among the top five firms in the “2015/2016 Best in ... Implementation Support and Staffing. KLAS is a research and insights firm on a ...
(Date:2/11/2016)... ... 11, 2016 , ... In a new paper published in ... Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance of upper ... surgeons when addressing this vital area. , The upper lateral cartilage in rhinoplasty, ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... ?" motivational speaker, trainer and author Ray Clarke poses a question as a ... fulfillment . In his book, "Being in the Being" (published by Partridge Singapore), ...
Breaking Medicine News(10 mins):